Fulvestrant
- Generic Name
- Fulvestrant
- Brand Names
- Faslodex, Fulvestrant Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C32H47F5O3S
- CAS Number
- 129453-61-8
- Unique Ingredient Identifier
- 22X328QOC4
- Background
Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. While it is used as monotherapy for the treatme...
- Indication
For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy, as monotherapy or in combination with other antineoplastic agents.
- Associated Conditions
- Advanced Breast Cancer, Advanced or Metastatic Breast Cancer
- Associated Therapies
- -
A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer
- First Posted Date
- 2021-09-23
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT05054374
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited protocol activity), Commack, New York, United States
🇺🇸Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States
Clinical Study of Chidamide Combined With Fulvestrant in the Treatment of Hormone Receptor-positive Advanced Breast Cancer
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2021-09-17
- Lead Sponsor
- Liaoning Tumor Hospital & Institute
- Target Recruit Count
- 82
- Registration Number
- NCT05047848
- Locations
- 🇨🇳
Liangning Tumor Hospital &Institute, Shenyang, Liaoning, China
Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-postitive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.
- Conditions
- Interventions
- First Posted Date
- 2021-09-09
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 234
- Registration Number
- NCT05038735
- Locations
- 🇪🇸
Novartis Investigative Site, Zaragoza, Spain
Comparative Effectiveness of Palbociclib Plus AI Versus Fulvestrant for HR+/HER2- ABC
- First Posted Date
- 2021-08-11
- Last Posted Date
- 2022-04-29
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 600
- Registration Number
- NCT05000736
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
Tucidinostat and Fulvestrant in Hormone-receptor Positive Advanced Breast Cancer
- First Posted Date
- 2021-08-11
- Last Posted Date
- 2021-08-11
- Lead Sponsor
- Guangdong Women and Children Hospital
- Target Recruit Count
- 73
- Registration Number
- NCT04999540
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-07-23
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 866
- Registration Number
- NCT04975308
- Locations
- 🇺🇸
USO - Texas Oncology - Allen, Allen, Texas, United States
🇦🇺Ashford Cancer Centre Research, Kurralta Park, South Australia, Australia
🇺🇸Ironwood Cancer & Research Centers, Chandler, Arizona, United States
Fulvestrant + Neratinib In Breast Cancer
- First Posted Date
- 2021-05-25
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Massachusetts General Hospital
- Registration Number
- NCT04901299
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant
- Conditions
- Interventions
- First Posted Date
- 2021-05-24
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 2
- Registration Number
- NCT04899349
- Locations
- 🇺🇸
Washington Uni School of Med Siteman Cancer Center, Saint Louis, Missouri, United States
🇲🇾Novartis Investigative Site, Kuala Lumpur, Malaysia
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
- Conditions
- Interventions
- First Posted Date
- 2021-04-28
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 895
- Registration Number
- NCT04862663
- Locations
- 🇻🇳
Research Site, Vinh, Vietnam
Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Mutation (PIK3CA) Treated With Alpelisib in Combination With Fulvestrant
- Conditions
- Interventions
- First Posted Date
- 2021-04-27
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 2
- Registration Number
- NCT04862143
- Locations
- 🇸🇪
Novartis Investigative Site, Orebro, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.